Important Notice for Affected Investors in Applied Therapeutics
Attention to all shareholders of Applied Therapeutics, Inc. This announcement serves as a crucial reminder of the class action lawsuit that has been initiated against the company. Investors who have experienced losses on their investments, particularly in connection with Applied Therapeutics (NASDAQ: APLT), are encouraged to engage with legal representation to understand their rights and options.
Details on the Class Action Lawsuit
The class action lawsuit addresses allegations that Applied Therapeutics, along with certain officers and directors, may have participated in fraudulent activities or engaged in unlawful business practices. If you have invested in the company during the class period, you may qualify to serve as a lead plaintiff. It's essential that you act promptly, as the deadline to file is approaching.
How to Get Involved
If you believe you are affected by these allegations, you are strongly advised to reach out for more information. Legal representatives are available to assist you and guide you through the process of becoming a lead plaintiff. It is crucial to provide your contact information along with the details of your investment for effective communication.
Key Dates to Remember
Shareholders will need to be proactive in their response, especially noting the critical deadline that restricts participation. You have until February 18, 2025, to file your intention to be appointed as a lead plaintiff in the ongoing class action lawsuit.
Recent Developments Affecting Applied Therapeutics
Recently, a significant announcement was made by Applied Therapeutics regarding a Complete Response Letter (CRL) issued by the U.S. Food and Drug Administration (FDA). This letter pertained to the company’s New Drug Application (NDA) for govorestat, highlighting concerns that could impact shareholder value.
Impact of FDA Communications
In the letter, the FDA stated that deficiencies were found within the clinical application that prevented the approval of the NDA in its current format. As a result, Applied Therapeutics witnessed a sharp decline in its stock price shortly after the announcement, reflecting investor concerns regarding the future of the company's product lines.
Stock Performance Trends
Following the disclosures from the FDA, Applied Therapeutics saw a decline of approximately 16.06%, closing at $8.57 per share. Subsequent communications disclosed ongoing issues that further affected the stock's performance, leading to a decrease to $1.29 per share over the course of just a few trading days. This financial turbulence has raised alarms among investors who are now more inclined to scrutinize the company’s future prospects.
About Pomerantz LLP
Pomerantz LLP is recognized as a frontrunner in corporate, securities, and antitrust class litigation. Since its inception over 85 years ago, the firm has remained committed to advocating for the rights of investors impacted by securities fraud and corporate misconduct. Their extensive track record includes recovering billions in damages for class members, showcasing a relentless pursuit of justice on behalf of harmed shareholders.
Contact Information
For those interested in engaging with Pomerantz LLP concerning the class action, you may reach out to legal representatives to discuss your circumstances. Providing your contact details is recommended for efficient responses.
Frequently Asked Questions
What is the class action lawsuit against Applied Therapeutics about?
The class action lawsuit addresses allegations of securities fraud and unlawful business practices by Applied Therapeutics and its officers.
Who can participate in the class action?
Shareholders who acquired Applied Therapeutics securities during the class period may be eligible to participate as lead plaintiffs.
What are the key deadlines for the lawsuit?
Investors interested in participating must file their request to be appointed as lead plaintiff by February 18, 2025.
How has recent news affected Applied Therapeutics' stock price?
Recent communications from the FDA regarding the New Drug Application have resulted in significant declines in the stock price, raising concerns among shareholders.
Where can affected investors get legal help?
Pomerantz LLP provides legal support for investors affected by the alleged fraudulent activities, guiding them through the process of joining the class action.
